Page last updated: 2024-12-08
pld118
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-amino-4-methylenecyclopentane-1-carboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 216240 |
| CHEMBL ID | 343803 |
| SCHEMBL ID | 117349 |
| MeSH ID | M0578134 |
Synonyms (33)
| Synonym |
|---|
| bay-10-8888 |
| cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1r,2s)- |
| (1r,2s)-2-amino-4-methylene-cyclopentanecarboxylic acid |
| icofungipen |
| pld-118 |
| pld118 |
| pld 118 |
| CHEMBL343803 |
| (-)-bay-10-8888 |
| (1r,2s)-2-amino-4-methylidenecyclopentane-1-carboxylic acid |
| AKOS006340643 |
| icofungipen [inn] |
| cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1r-cis)- |
| bay 10-8888 |
| 198022-65-0 |
| i20202q8m8 , |
| 2-amino-4-methylenecyclopentane-1-carboxylic acid |
| (1r,2s)-2-amino-4-methylenecyclopentane-1-carboxylic acid |
| unii-i20202q8m8 |
| 156292-16-9 |
| 872691-28-6 |
| RKOUGZGFAYMUIO-RITPCOANSA-N |
| SCHEMBL117349 |
| DTXSID90173515 |
| 156292-48-7 |
| cyclopentanecarboxylic acid, 2-amino-4-methylene-, cis- (9ci) |
| cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1s,2r)- (9ci) |
| 2-amino-4-methylidenecyclopentane-1-carboxylic acid |
| bay 10-8888; pld 118 |
| Q27280267 |
| cyclopentanecarboxylic acid,2-amino-4-methylene-,cis-(9ci) |
| HY-106997 |
| CS-0027085 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Icofungipen shows nearly complete oral bioavailability in a variety of species, and its in vivo efficacy indicates its potential for the oral treatment of yeast infections." | ( In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Ergovic, G; Galic, T; Geschke, U; Hasenoehrl, A; Marsic, N; Mittendorf, J; Schmidt, A; Schoenfeld, W; Skerlev, M, 2006) | 0.33 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " PLD-118 demonstrated nonlinear plasma pharmacokinetics across the investigated dosage range, as was evident from a dose-dependent increase in plasma clearance and a dose-dependent decrease in the area under the plasma concentration-time curve." | ( Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Bacher, J; Groll, AH; Kelaher, AM; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ, 2004) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1380106 | Inhibition of Saccharomyces cerevisiae IleRS | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Emerging New Targets for the Treatment of Resistant Fungal Infections. |
| AID47250 | In vitro inhibitory activity against Candida albicans | 2003 | Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3 | Novel antifungal beta-amino acids: synthesis and activity against Candida albicans. |
| AID1380099 | Half life in human | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Emerging New Targets for the Treatment of Resistant Fungal Infections. |
| AID1380102 | Oral bioavailability in rabbit | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Emerging New Targets for the Treatment of Resistant Fungal Infections. |
| AID1380101 | Oral bioavailability in dog | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Emerging New Targets for the Treatment of Resistant Fungal Infections. |
| AID1380100 | Oral bioavailability in rat | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Emerging New Targets for the Treatment of Resistant Fungal Infections. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 14.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (14.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (15.38%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||